At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AARD Aardvark Therapeutics
Pre-Mkt 02-20 06:03:11 EST
12.41
-0.24
-1.90%
High12.61Low12.06Vol52.36K
Open12.61D1 Closing12.65Amplitude4.39%
Mkt Cap269.26MTradable Cap73.07MTotal Shares21.70M
T/O643.40KT/O Rate0.89%Tradable Shares5.89M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BRIEF-Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Reuters  ·  02-13
BRIEF-Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Aardvark Therapeutics Grants Stock Options to New Employees
Reuters  ·  02-13
Aardvark Therapeutics Grants Stock Options to New Employees
BRIEF-Aardvark Therapeutics Announces Establishment Of New U.S. Subsidiary
Reuters  ·  02-12
BRIEF-Aardvark Therapeutics Announces Establishment Of New U.S. Subsidiary
Aardvark Therapeutics Launches Ardia Subsidiary for Dermatology Pipeline Expansion
Reuters  ·  02-12
Aardvark Therapeutics Launches Ardia Subsidiary for Dermatology Pipeline Expansion
Aardvark Therapeutics Appoints Derrick C. Li as Chief Business Officer and Expands Nelson Sun's Role
Reuters  ·  02-12
Aardvark Therapeutics Appoints Derrick C. Li as Chief Business Officer and Expands Nelson Sun's Role
Bryan Jones Named CEO as Aardvark Therapeutics Launches Ardia Subsidiary
Reuters  ·  02-12
Bryan Jones Named CEO as Aardvark Therapeutics Launches Ardia Subsidiary
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer
THOMSON REUTERS  ·  02-12
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer
Aardvark Therapeutics Announces Leadership Appointments
GlobeNewswire  ·  02-12
Aardvark Therapeutics Announces Leadership Appointments
Aardvark Therapeutics Price Target Maintained With a $26.00/Share by BTIG
Dow Jones  ·  02-11
Aardvark Therapeutics Price Target Maintained With a $26.00/Share by BTIG
BRIEF-Aardvark Therapeutics Announces FDA Submission And Irb Approval Of Amended Trial Protocol
Reuters  ·  02-10
BRIEF-Aardvark Therapeutics Announces FDA Submission And Irb Approval Of Amended Trial Protocol
Aardvark announces FDA submission, IRB approval of amended trial protocol
TIPRANKS  ·  02-10
Aardvark announces FDA submission, IRB approval of amended trial protocol
Aardvark Therapeutics Receives IRB Approval for Expanded Phase 3 HERO Trial Eligibility
Reuters  ·  02-10
Aardvark Therapeutics Receives IRB Approval for Expanded Phase 3 HERO Trial Eligibility
Aardvark Therapeutics Announces FDA Submission and Irb Approval of Amended Trial Protocol for Lead Candidate Ard-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome
THOMSON REUTERS  ·  02-10
Aardvark Therapeutics Announces FDA Submission and Irb Approval of Amended Trial Protocol for Lead Candidate Ard-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome
Aardvark Therapeutics Inc - Hero Trial Enrollment on Track to Report Data Q3 2026
THOMSON REUTERS  ·  02-10
Aardvark Therapeutics Inc - Hero Trial Enrollment on Track to Report Data Q3 2026
Aardvark Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Dow Jones  ·  02-09
Aardvark Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
B. Riley Initiates Aardvark Therapeutics at Buy With $32 Price Target
MT Newswires Live  ·  01-28
B. Riley Initiates Aardvark Therapeutics at Buy With $32 Price Target
Aardvark Therapeutics Inc : B. Riley Initiates Coverage With Buy Rating; Target Price $32
THOMSON REUTERS  ·  01-28
Aardvark Therapeutics Inc : B. Riley Initiates Coverage With Buy Rating; Target Price $32
Aardvark Therapeutics initiated with a Buy at B. Riley
TIPRANKS  ·  01-28
Aardvark Therapeutics initiated with a Buy at B. Riley
Ten new option listings and two option delistings on January 22nd
TIPRANKS  ·  01-22
Ten new option listings and two option delistings on January 22nd
Aardvark Therapeutics: Clinical Momentum and 2026 Catalyst Stack Underpin Buy Rating and $26 Target
TIPRANKS  ·  01-20
Aardvark Therapeutics: Clinical Momentum and 2026 Catalyst Stack Underpin Buy Rating and $26 Target

Introduction

Company Name.
Aardvark Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--